Piramal launches integrated platform for CDMO services

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/NicoElNino)
(Image: Getty/NicoElNino)
The contract development and manufacturing organization (CDMO) Piramal Pharma Solutions has launched its Xcelerate Integrated Solutions platform.

Over the last two years, Piramal Pharma Solutions (PPS) has integrated its drug discovery and commercialization services, while addressing gaps through acquisitions and internal investment, according to the company.

The CDMO’s platform provides integrated solutions for orphan diseases, niche therapies, and fast track medicines.

Mr. Vivek Sharma, CEO, Piramal Pharma Solutions said in a press release, "This platform is a result of the growing interest from our customers on structuring preferred relationships with global leaders such as Piramal who can offer end-to-end solutions, coupled with our desire to collaborate with strategic partners."

PPS has 12 research and development and manufacturing locations across North America, Europe, and Asia.

Its consolidated revenues were more than $1.6bn in FY2018, with around 46% of revenues generated from outside India.

PPS has not responded to a request for comment.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars